nortriptyline has been researched along with Asialia in 10 studies
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with CBT + bupropion resulted in a better 6-month rate of smoking cessation compared to CBT+nortriptyline or CBT + placebo." | 9.12 | A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. ( Cesari, DH; Chatkin, JM; Fam, CF; Fritscher, CC; Haggsträm, FM; Sussenbach-Vaz, E, 2006) |
| "Gabapentin was shown to be equally efficacious but was better tolerated compared to nortriptyline and can be considered a suitable alternative for the treatment of PHN." | 6.72 | Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial. ( Chandra, K; Gupta, S; Malhotra, S; Pandhi, P; Shafiq, N, 2006) |
| "Treatment with CBT + bupropion resulted in a better 6-month rate of smoking cessation compared to CBT+nortriptyline or CBT + placebo." | 5.12 | A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. ( Cesari, DH; Chatkin, JM; Fam, CF; Fritscher, CC; Haggsträm, FM; Sussenbach-Vaz, E, 2006) |
| "First-line neuropathic pain drugs, including tricyclic antidepressants, are not always effective, and opioids have been recommended as second line." | 2.80 | Combination of morphine with nortriptyline for neuropathic pain. ( DuMerton-Shore, D; Gilron, I; Holden, RR; Jackson, AC; Tu, D, 2015) |
| "Gabapentin was shown to be equally efficacious but was better tolerated compared to nortriptyline and can be considered a suitable alternative for the treatment of PHN." | 2.72 | Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial. ( Chandra, K; Gupta, S; Malhotra, S; Pandhi, P; Shafiq, N, 2006) |
| " At the end of each study week, the steady-state pharmacokinetic parameters of nortriptyline or paroxetine were determined within the dose interval." | 2.70 | Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. ( Andersson, K; Bertilsson, L; Härtter, S; Laine, K; Svensson, JO; Tybring, G; Widén, J, 2001) |
| " The results of the investigation were: (1) long-term treatment with nortriptyline is followed by hyposecretion or xerostomia, (2) the reduction of the secretion is reversible, (3) re-establishment of treatment with dosage leading to the same serum level of nortriptyline is immediately followed by a drop in saliva secretion, and (4) the changes in salivary secretion are useful as an indicator of side effects." | 1.26 | Saliva secretion following long-term antidepressant treatment with nortriptyline controlled by plasma levels. ( Bertram, U; Kragh-Sørensen, P; Larsen, NE; Rafaelsen, OJ, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gilron, I | 1 |
| Tu, D | 1 |
| Holden, RR | 1 |
| Jackson, AC | 1 |
| DuMerton-Shore, D | 1 |
| Uher, R | 1 |
| Farmer, A | 1 |
| Henigsberg, N | 1 |
| Rietschel, M | 1 |
| Mors, O | 1 |
| Maier, W | 1 |
| Kozel, D | 1 |
| Hauser, J | 1 |
| Souery, D | 1 |
| Placentino, A | 1 |
| Strohmaier, J | 1 |
| Perroud, N | 1 |
| Zobel, A | 1 |
| Rajewska-Rager, A | 1 |
| Dernovsek, MZ | 1 |
| Larsen, ER | 1 |
| Kalember, P | 1 |
| Giovannini, C | 1 |
| Barreto, M | 1 |
| McGuffin, P | 1 |
| Aitchison, KJ | 1 |
| Haggsträm, FM | 1 |
| Chatkin, JM | 1 |
| Sussenbach-Vaz, E | 1 |
| Cesari, DH | 1 |
| Fam, CF | 1 |
| Fritscher, CC | 1 |
| Chandra, K | 1 |
| Shafiq, N | 1 |
| Pandhi, P | 1 |
| Gupta, S | 1 |
| Malhotra, S | 1 |
| Pollock, BG | 1 |
| Mulsant, BH | 1 |
| Nebes, R | 1 |
| Kirshner, MA | 1 |
| Begley, AE | 1 |
| Mazumdar, S | 2 |
| Reynolds, CF | 2 |
| Marraccini, RL | 1 |
| Houck, PR | 1 |
| Miller, MD | 1 |
| Frank, E | 1 |
| Perel, JM | 1 |
| Cornes, C | 1 |
| Kupfer, DJ | 1 |
| Laine, K | 1 |
| Tybring, G | 1 |
| Härtter, S | 1 |
| Andersson, K | 1 |
| Svensson, JO | 1 |
| Widén, J | 1 |
| Bertilsson, L | 1 |
| Bertram, U | 1 |
| Kragh-Sørensen, P | 1 |
| Rafaelsen, OJ | 1 |
| Larsen, NE | 1 |
| Georgotas, A | 1 |
| McCue, RE | 1 |
| Hapworth, W | 1 |
| Friedman, E | 1 |
| Kim, OM | 1 |
| Welkowitz, J | 1 |
| Chang, I | 1 |
| Cooper, TB | 1 |
| Malitz, S | 1 |
| Kanzler, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens: SPHERE[NCT02625155] | Phase 4 | 14,000 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain[NCT02339662] | Phase 4 | 50 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 trials available for nortriptyline and Asialia
| Article | Year |
|---|---|
Combination of morphine with nortriptyline for neuropathic pain.
Topics: Adult; Affect; Aged; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Constipation; Double-Blin | 2015 |
Adverse reactions to antidepressants.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Male; Middle Ag | 2009 |
A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results.
Topics: Adrenergic Uptake Inhibitors; Bupropion; Counseling; Delayed-Action Preparations; Double-Blind Metho | 2006 |
Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial.
Topics: Aged; Amines; Analgesics; Capsules; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; D | 2006 |
Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline.
Topics: Aged; Cholinergic Antagonists; Depressive Disorder; Humans; Nortriptyline; Paroxetine; Radioligand A | 1998 |
A double-blind, placebo-controlled assessment of nortriptyline's side-effects during 3-year maintenance treatment in elderly patients with recurrent major depression.
Topics: Aged; Analysis of Variance; Antidepressive Agents, Tricyclic; Body Mass Index; Body Weight; Constipa | 1999 |
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Topics: Adult; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors | 2001 |
Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly.
Topics: Aged; Depressive Disorder; Dizziness; Female; Humans; Male; Middle Aged; Nortriptyline; Phenelzine; | 1986 |
Are antidepressants better than placebo?
Topics: Adjustment Disorders; Adult; Aged; Amitriptyline; Antidepressive Agents; Anxiety; Clinical Trials as | 1971 |
1 other study available for nortriptyline and Asialia
| Article | Year |
|---|---|
Saliva secretion following long-term antidepressant treatment with nortriptyline controlled by plasma levels.
Topics: Aged; Ascorbic Acid; Bipolar Disorder; Carbonates; Female; Humans; Male; Middle Aged; Nortriptyline; | 1979 |